Danaher posted Q1 adjusted EPS $2.06 beating consensus $1.94, but revenue $5.95B missed $5.99B estimate.
Revenue shortfall stemmed from a lighter-than-typical respiratory season at Cepheid, offset by strength in Bioprocessing and Life Sciences.
Danaher lifted FY adjusted EPS guidance to $8.35-$8.55 and maintained 3%‑6% core revenue growth outlook.
CEO Rainer M. Blair highlighted $1.3B operating cash flow, $1.1B free cash flow and announced intent to acquire Masimo Corp.